Approved TCEs
| INN . | Brand name . | Target . | Company . | Approval date . | Indication . | Dose and schedule . | Route . | References . |
|---|---|---|---|---|---|---|---|---|
| Blinatumomab | Blincyto | CD19 | Amgen | December 3, 2014 | MRD+ or r/r or CP CD19+ B-ALL | MRD+, ≥45 kg body weight: four cycles of days 1–28, 28 μg/day continuous infusion; days 29–42, no treatment. r/r: induction cycle 1, days 1–7, 9 μg/day; days 8–28, 28 μg/day; days 29–42, no treatment. Induction cycle 2, days 1–28, 28 μg/day; days 29–42, no treatment. Consolidation cycles 3–5, days 1–28, 28 μg/day; days 29–42, no treatment. Cycles 6–9, days 1–28, 28 μg/day, days 29–84, no treatment. CP: consolidation cycle, days 1–28, 28 μg/day; days 29–42, no treatment. | IV infusion | Amgen (2024a), FDA (2025), Herrera et al. (2024) |
| Tebentafusp-tebn | Kimmtrak | gp100/HLA-A*02:01 | Immunocore | January 25, 2022 | HLA-A*02:01+ unresectable or metastatic UM | Weekly. Day 1, 20 μg; day 8, 30 μg; then 68 μg weekly. | IV infusion | FDA (2025), Hassel et al. (2023), Herrera et al. (2024), Immunocore (2024) |
| Teclistamab-cqyv | Tecvayli | BCMA | Janssen | October 25, 2022 | r/r MM | Weekly cycles. Cycle 1 step-up, 0.06–1.5 mg/kg; week 2+, 1.5 mg/kg. Patients with CR ≥ 6 m: 1.5 mg/kg every 2 wk. | SC injection | FDA (2025), Herrera et al. (2024), Janssen Biotech (2024) |
| Mosunetuzumab-axgb | Lunsumio | CD20 | Roche/Genentech | December 22, 2022 | r/r FL | 21 day cycles. Cycle 1 step-up, 1–60 mg; cycle 2, 60 mg, cycle 3+, 30 mg. | IV infusion | Budde et al. (2022b), FDA (2025), Genentech (2024), Herrera et al. (2024), Strohl (2024) |
| Epcoritamab-bysp | Epkinly | CD20 | AbbVie/Genmab | May 19, 2023 | r/r DLBCL, r/r FL | 28 day cycles. Cycle 1 step-up, 0.16–48 mg weekly. Cycles 2/3, 48 mg weekly. Cycles 4–9, 48 mg biweekly. Cycle 10+, 48 mg every 4 wk. | SC injection | FDA (2025), Genmab (2024), Herrera et al. (2024), Strohl (2024) |
| Glofitamab-gxbm | Columvi | CD20 | Roche/Genentech | June 15, 2023 | r/r DLBCL, NOS DLBCL, LBCL | 21 day cycles. Cycle 1, day 1, obinutuzumab 1,000 mg pretreatment; day 8, 2.5 mg Columvi, day 15, 10 mg. Cycle 2–12, day 1, 30 mg. | IV infusion | FDA (2025), Genentech (2023), Herrera et al. (2024), Strohl (2024) |
| Talquetamab-tgvs | Talvey | GPRC5D | Janssen | August 9, 2023 | r/r MM | Two schedules. Weekly schedule: Cycle 1 step-up, day 1, 0.01 mg/kg; day 4, 0.06 mg/kg; day 7, 0.4 mg/kg. Then 0.4 mg/kg once weekly. Biweekly schedule: Cycle 1 as above. Day 10, 0.8 mg/kg; then 0.8 mg/kg every 2 wk. | SC injection | Janssen Biotech (2023), FDA (2025), Herrera et al. (2024), Strohl (2024) |
| Elranatamab-bcmm | Elrexfio | BCMA | Pfizer | August 14, 2023 | r/r MM | Two schedules. Weekly schedule: Cycle 1 step-up, day 1, 12 mg; day 4, 32 mg; day 8, 76 mg. Then 76 mg weekly through week 24. Biweekly schedule: responders only. Starting at week 25, 76 mg every 2 wk. | SC injection | FDA (2025), Herrera et al. (2024), Pfizer (2023), Strohl (2024) |
| Tarlatamab-dlle | Imdelltra | DLL3 | Amgen | May 16, 2024 | Pretreated ES-SCLC | Biweekly cycles. Cycle 1 step-up, day 1, 1 mg; day 8, 10 mg; day 15, 10 mg. Cycle 2+, days 1 and 15, 10 mg each. | IV infusion | Amgen (2024b), FDA (2025), Herrera et al. (2024) |
| Odronextamab | Ordspono | CD20 | Regeneron | August 22, 2024 (EMA) | r/r DLBCL, r/r FL | Four 21-day cycles followed by biweekly or monthly maintenance. Cycle 1 step-up, day 1, 0.2 mg, day 2, 0.5 mg, days 8 and 9, 2 mg, days 15 and 16, 10 mg. Cycles 2–4, 80 mg (r/r FL) or 160 mg (r/r DLBCL) on days 1, 8 and 15. Maintenance, 160 mg (r/r FL) or 320 mg (r/r DLBCL) biweekly. Reduce to monthly after CR duration of 9 mo. | IV infusion | Blair (2024), EMA (2024), Regeneron Pharmaceuticals (2025b) |
| Catumaxomab | Korjuny | EpCAM | Lindis Biotech, licensed to Pharmanovia | February 10, 2025 (EMA) | Malignant ascites in adults with EpCAM+ carcinomas | Four IP infusions of 10, 20, 50, and 150 μg on days 0, 3, 7, and 10, respectively. | IP infusion | EMA (2025), Syed (2025) |
| Linvoseltamab-gcpt | Lynozyfic | BCMA | Regeneron | July 2, 2025 | r/r MM | Step-up: three ascending doses of 5 mg on week 1 day 1, 25 mg on week 2 day 1, and 200 mg on week 3 day 1. Then 200 mg weekly in week 4–13, followed by 200 mg every 2 wk. Patients who have received at least 17 doses of 200 mg and shown confirmed very good PRs or better at or after week 24 can switch to once every 4 wk. | IP infusion | FDA (2025), Regeneron Pharmaceuticals (2025a) |
| INN . | Brand name . | Target . | Company . | Approval date . | Indication . | Dose and schedule . | Route . | References . |
|---|---|---|---|---|---|---|---|---|
| Blinatumomab | Blincyto | CD19 | Amgen | December 3, 2014 | MRD+ or r/r or CP CD19+ B-ALL | MRD+, ≥45 kg body weight: four cycles of days 1–28, 28 μg/day continuous infusion; days 29–42, no treatment. r/r: induction cycle 1, days 1–7, 9 μg/day; days 8–28, 28 μg/day; days 29–42, no treatment. Induction cycle 2, days 1–28, 28 μg/day; days 29–42, no treatment. Consolidation cycles 3–5, days 1–28, 28 μg/day; days 29–42, no treatment. Cycles 6–9, days 1–28, 28 μg/day, days 29–84, no treatment. CP: consolidation cycle, days 1–28, 28 μg/day; days 29–42, no treatment. | IV infusion | Amgen (2024a), FDA (2025), Herrera et al. (2024) |
| Tebentafusp-tebn | Kimmtrak | gp100/HLA-A*02:01 | Immunocore | January 25, 2022 | HLA-A*02:01+ unresectable or metastatic UM | Weekly. Day 1, 20 μg; day 8, 30 μg; then 68 μg weekly. | IV infusion | FDA (2025), Hassel et al. (2023), Herrera et al. (2024), Immunocore (2024) |
| Teclistamab-cqyv | Tecvayli | BCMA | Janssen | October 25, 2022 | r/r MM | Weekly cycles. Cycle 1 step-up, 0.06–1.5 mg/kg; week 2+, 1.5 mg/kg. Patients with CR ≥ 6 m: 1.5 mg/kg every 2 wk. | SC injection | FDA (2025), Herrera et al. (2024), Janssen Biotech (2024) |
| Mosunetuzumab-axgb | Lunsumio | CD20 | Roche/Genentech | December 22, 2022 | r/r FL | 21 day cycles. Cycle 1 step-up, 1–60 mg; cycle 2, 60 mg, cycle 3+, 30 mg. | IV infusion | Budde et al. (2022b), FDA (2025), Genentech (2024), Herrera et al. (2024), Strohl (2024) |
| Epcoritamab-bysp | Epkinly | CD20 | AbbVie/Genmab | May 19, 2023 | r/r DLBCL, r/r FL | 28 day cycles. Cycle 1 step-up, 0.16–48 mg weekly. Cycles 2/3, 48 mg weekly. Cycles 4–9, 48 mg biweekly. Cycle 10+, 48 mg every 4 wk. | SC injection | FDA (2025), Genmab (2024), Herrera et al. (2024), Strohl (2024) |
| Glofitamab-gxbm | Columvi | CD20 | Roche/Genentech | June 15, 2023 | r/r DLBCL, NOS DLBCL, LBCL | 21 day cycles. Cycle 1, day 1, obinutuzumab 1,000 mg pretreatment; day 8, 2.5 mg Columvi, day 15, 10 mg. Cycle 2–12, day 1, 30 mg. | IV infusion | FDA (2025), Genentech (2023), Herrera et al. (2024), Strohl (2024) |
| Talquetamab-tgvs | Talvey | GPRC5D | Janssen | August 9, 2023 | r/r MM | Two schedules. Weekly schedule: Cycle 1 step-up, day 1, 0.01 mg/kg; day 4, 0.06 mg/kg; day 7, 0.4 mg/kg. Then 0.4 mg/kg once weekly. Biweekly schedule: Cycle 1 as above. Day 10, 0.8 mg/kg; then 0.8 mg/kg every 2 wk. | SC injection | Janssen Biotech (2023), FDA (2025), Herrera et al. (2024), Strohl (2024) |
| Elranatamab-bcmm | Elrexfio | BCMA | Pfizer | August 14, 2023 | r/r MM | Two schedules. Weekly schedule: Cycle 1 step-up, day 1, 12 mg; day 4, 32 mg; day 8, 76 mg. Then 76 mg weekly through week 24. Biweekly schedule: responders only. Starting at week 25, 76 mg every 2 wk. | SC injection | FDA (2025), Herrera et al. (2024), Pfizer (2023), Strohl (2024) |
| Tarlatamab-dlle | Imdelltra | DLL3 | Amgen | May 16, 2024 | Pretreated ES-SCLC | Biweekly cycles. Cycle 1 step-up, day 1, 1 mg; day 8, 10 mg; day 15, 10 mg. Cycle 2+, days 1 and 15, 10 mg each. | IV infusion | Amgen (2024b), FDA (2025), Herrera et al. (2024) |
| Odronextamab | Ordspono | CD20 | Regeneron | August 22, 2024 (EMA) | r/r DLBCL, r/r FL | Four 21-day cycles followed by biweekly or monthly maintenance. Cycle 1 step-up, day 1, 0.2 mg, day 2, 0.5 mg, days 8 and 9, 2 mg, days 15 and 16, 10 mg. Cycles 2–4, 80 mg (r/r FL) or 160 mg (r/r DLBCL) on days 1, 8 and 15. Maintenance, 160 mg (r/r FL) or 320 mg (r/r DLBCL) biweekly. Reduce to monthly after CR duration of 9 mo. | IV infusion | Blair (2024), EMA (2024), Regeneron Pharmaceuticals (2025b) |
| Catumaxomab | Korjuny | EpCAM | Lindis Biotech, licensed to Pharmanovia | February 10, 2025 (EMA) | Malignant ascites in adults with EpCAM+ carcinomas | Four IP infusions of 10, 20, 50, and 150 μg on days 0, 3, 7, and 10, respectively. | IP infusion | EMA (2025), Syed (2025) |
| Linvoseltamab-gcpt | Lynozyfic | BCMA | Regeneron | July 2, 2025 | r/r MM | Step-up: three ascending doses of 5 mg on week 1 day 1, 25 mg on week 2 day 1, and 200 mg on week 3 day 1. Then 200 mg weekly in week 4–13, followed by 200 mg every 2 wk. Patients who have received at least 17 doses of 200 mg and shown confirmed very good PRs or better at or after week 24 can switch to once every 4 wk. | IP infusion | FDA (2025), Regeneron Pharmaceuticals (2025a) |
CP, consolidation phase; HLA, human leukocyte antigen; NOS, not otherwise specified; PR, partial response; r/r, relapsed or refractory.